Free press releases distribution network?

Agency / Source: Foamix Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Foamix Receives US Patent for Oleaginous Foam - Oleaginous foams – ideal vehicles for lipophilic and water-sensitive drugs, such as vitamin D, retinoids and lipophilic antibiotics
Foamix Receives US Patent for Oleaginous Foam

 

PRZOOM - /newswire/ - Rehovot, Israel, 2010/11/04 - Oleaginous foams – ideal vehicles for lipophilic and water-sensitive drugs, such as vitamin D, retinoids and lipophilic antibiotics.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Foamix Ltd., a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, today announced that the United States Patent and Trademark Office has issued US Patent 7,820,145, entitled “Oleaginous Pharmaceutical and Cosmetic Foam”. The patent covers novel foam formulations comprising hydrophobic solvents and or silicone oils as the main component. The claimed formulations can be water-free or alternatively can include up to 30% water.

Oleaginous foams are cosmetically-elegant and easy to use. They spread freely on the skin and absorb readily with a simple rub. They can be used as carriers for a variety of hydrophobic drugs, including drugs that degrade in the presence of water.

Foamix has incorporated a wide variety of drugs into its oleaginous foam, including various corticosteroids, vitamin D analogs, retinoids and lipophilic antibiotics.
This patent is the fifth to be issued to Foamix in the United States within the last 12 months, which collectively provides Foamix with protection for its emollient foam, hydrophilic waterless foam, iodine foam, oleaginous foam, and saccharide foam technologies. A further four issued US patents provide coverage for the Company’s proprietary OilGel™ technology.
“We work hard to realize our unique development capabilities and to provide our products and our partners products with long-term market exclusivity” said Dov Tamarkin, PhD, CEO of Foamix. “This patent is an important component of Foamix’s developing intellectual property portfolio covering a broad platform of topical delivery systems and their respective drug products.”

About Foamix
Headquartered in Rehovot, Israel, Foamix Ltd. (foamix.co.il) is a clinical-stage, privately held specialty pharmaceutical company, focused on the development of proprietary topical foam and OilGel™ products for prescription, OTC and cosmetic applications. Foamix creates advanced products with improved convenience, higher compliance and better efficacy, which are backed by an extensive patent portfolio. The company’s development capabilities range from initial development of the formulations to scale-up, GMP manufacturing, preclinical and clinical studies.

Foamix partners with leading pharmaceutical companies, including Intendis (Bayer’s dermatology company), Dr. Reddy's and Ferndale Laboratories.
Foamix has a strong in-house pipeline of dermatological and gynecological drugs. The Company’s lead product, Topical Minocycline, is currently in Phase II clinical studies.
To date, Foamix has 9 issued patents in the United States, covering its foam and OilGel™ technology platforms. The company has an additional 150 applications and patents worldwide, of which more than 60 applications are filed in the U.S.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Foamix Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Foamix Receives US Patent for Oleaginous Foam

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Sigal Maymon - Foamix.co.il 
+972 8 9316233 sigal[.]foamix.co.il
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Foamix Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Foamix Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  MagLar, Inc.

Visit  NAKIVO, Inc.

Visit  BizJobs.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today